Insights

Why Novavax Stock Dipped, Then Soared, on Monday

What happened
Just after the market opened on Monday, Novavax (NASDAQ: NVAX) shares were hit by an investor sell-off. This was an immediate, sharply negative reaction to a set of Food and Drug Administration (FDA) briefing documents concerning the company’s NVX-CoV2373 coronavirus vaccine.
However, probably realizing that this reaction was panic-driven and perhaps unjustified, Novavax’s shares staged an impressive recovery. They ultimately notched a gain on the day, closing more than 6% higher and trouncing the S&P 500 index.
So what
The source of investor concern was the FDA’s citing of four cases of myocarditis, a heart inflammation, recorded among the patients of a phase 3 clinical trial of the vaccine. The regulator wrote in its briefing, “These events raise the concern for a causal association with this vaccine, similar to the association documented with mRNA COVID-19 vaccines.”
Image source: Getty Images.

Any instance of a potentially fatal illness arising from vaccine administration is, of course, serious cause for concern. 
But it’s worth zooming out to look at the bigger picture. Nearly 30,000 individuals participated in the late-stage trial conducted by the vaccine specialist, which, by the way, demonstrated that NVX-CoV2373 had an efficacy of over 90%.
The FDA wrote that based on this performance that “it is more likely than not that the vaccine will provide some meaningful level of protection against COVID-19 due to Omicron, in particular against more severe disease.”
Now what
Novavax also did an admirable job in quickly reassuring the world that our current understanding of myocarditis as it relates to coronavirus vaccines is a “correlation does not imply causation” situation.
“Throughout the pandemic, as publicly available vaccines have been administered, there have been numerous investigations into findings related to myocarditis,” the company wrote in a press release published Monday. “We have learned that we can expect to see natural background events of myocarditis in any sufficiently large database, and that young males are at higher risk. Myocarditis is most often caused by nonspecific viral infections.”  
Novavax added that it will continue to “monitor all adverse events.” 
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Just after the market opened on Monday, Novavax (NASDAQ: NVAX) shares were hit by an investor sell-off. This was an immediate, sharply negative reaction to a set of Food and Drug Administration (FDA) briefing documents concerning the company’s NVX-CoV2373 coronavirus vaccine.

However, probably realizing that this reaction was panic-driven and perhaps unjustified, Novavax’s shares staged an impressive recovery. They ultimately notched a gain on the day, closing more than 6% higher and trouncing the S&P 500 index.

So what

The source of investor concern was the FDA’s citing of four cases of myocarditis, a heart inflammation, recorded among the patients of a phase 3 clinical trial of the vaccine. The regulator wrote in its briefing, “These events raise the concern for a causal association with this vaccine, similar to the association documented with mRNA COVID-19 vaccines.”

Image source: Getty Images.

Any instance of a potentially fatal illness arising from vaccine administration is, of course, serious cause for concern. 

But it’s worth zooming out to look at the bigger picture. Nearly 30,000 individuals participated in the late-stage trial conducted by the vaccine specialist, which, by the way, demonstrated that NVX-CoV2373 had an efficacy of over 90%.

The FDA wrote that based on this performance that “it is more likely than not that the vaccine will provide some meaningful level of protection against COVID-19 due to Omicron, in particular against more severe disease.”

Now what

Novavax also did an admirable job in quickly reassuring the world that our current understanding of myocarditis as it relates to coronavirus vaccines is a “correlation does not imply causation” situation.

“Throughout the pandemic, as publicly available vaccines have been administered, there have been numerous investigations into findings related to myocarditis,” the company wrote in a press release published Monday. “We have learned that we can expect to see natural background events of myocarditis in any sufficiently large database, and that young males are at higher risk. Myocarditis is most often caused by nonspecific viral infections.”  

Novavax added that it will continue to “monitor all adverse events.” 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here To Get Started
FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here For More Info